Smith Kline & French Laboratories Limited

Glaxo Group Limited

Boehringer Mannheim Gmbh

Sk&f Laboratories Ltd.

David G Cooper

George S Sach

Ian Thomson Forbes

Vincenzo Garzya

Paul Adrian Wyman

Jian Jin

Brian W Budzik

Dongchuan Shi

Graham Walker

Dale James Johnson

Paul William Smith

Graeme Irvine Stevenson

Rodney C Young

Deirdre M Hickey

Peter D Miles

Robert John Ife

Ernst-Christian Witte

Robert A Slater

Karlheinz Stegmeier

Andrew D Gribble

Albert A Jaxa-Chamiec

Compounds of formula (I) and salts and solvates are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Compounds which have activity at M1 receptor and their uses in medicine

Compounds of formula (I) or a salt thereof are provided: wherein R, R, R, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

[object Object]

Compounds of formula (I) and salts thereof are provided: wherein R, R, R, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Compounds of formula (I) and salts are provided: wherein Ris selected from hydrogen, halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or Calkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Benzimidazolones which have activity at M1 receptor

Compounds of formula (I) and salts are provided: wherein Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or Calkyl. The compounds are Magonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Compounds of formula (I) and salts are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

##STR1## Substituted 4,5-diaryl-2-imidazolones of structure (I), in which each group AR is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl; R.sup.1 is hydrogen, alkyl, optionally substituted phenyl or optionally substituted heteroaryl; n is 4 to 12; and X is 5-tetrazolyl, SO.sub.3 H, P(O)(OR).sub.2, P(O)(OH).sub.2 or P(O)(R)(OR) in which R is hydrogen acceptable salt thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, inter alia, in the treatment of cardiovascular disorders.

Substituted 2-imidazolone derivatives, their preparation and

Phenylalkanoic acids containing a sulphonamido group, and their use in a method of treatment of thromboxane-A.sub.2 mediated diseases are disclosed. A compound of the invention is 4-[4-(phenyl-sulphonamido)phenyl]butyric acid.

Sulphonamido containing phenylalkanoic acids as thromboxane A.sub.2

Pyridiniomethacrylate polymers are described which are of use in the treatment of elevated serum cholesterol levels. A compound of the invention is cross-linked 3-(N-methyl-3-pyridinio)propyl methacrylate chloride.

Crosslinked pyridinomethacrylate polymers

The invention relates to phenylsulphonamidolkanoic acids which have thromboxane A.sub.2 receptor antagonist activity.

Biologically active compounds

The invention provides a class of alkanoic acids substituted with a benzenesulphonamidopyridyl group. The compounds have activity as thromboxane A.sub.2 -antagonists.

Benzenesulphonamidopyridyl compounds which are useful as thromboxane A.sub.

This invention relates to 2-pyridine derivatives substituted in the 4-position with a dialkylamino- or piperidinyl- or pyrrolidinylalkyl group. The compounds have histamine H.sub.2 -antagonist activity.

Pyridine compounds which have useful histamine-H.sub.2 antagonist

The disclosure relates to a class of 2-(pyridylalkylamino)-3-hydroxypyridines which are active as histamine H.sub.1 -antagonists.

Growing community of inventors

Letchworth, United Kingdom

David G Cooper